Lenalidomide therapy in myelofibrosis with myeloid metaplasia. - sprookjes - yvandenbroek - TriplyDB

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

http://www.wikidata.org/entity/Q33370821

about

Mechanism of action of lenalidomide in hematological malignancies Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors Advances in the management of myelofibrosis Pomalidomide is active in the treatment of anemia associated with myelofibrosis Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.A phase-2 trial of low-dose pomalidomide in myelofibrosis.Immunomodulatory agents in myelofibrosis.Emerging drugs for myelofibrosis.Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Managing patients with myelofibrosis and low platelet counts.Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.Rare cancers: Challenges & issues.Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.Modest activity of pomalidomide in patients with myelofibrosis and significant anemia Successful control of acute myelofibrosis with lenalidomide.Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Choosing between stem cell therapy and drugs in myelofibrosis.Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.Profile of pomalidomide and its potential in the treatment of myelofibrosis.Chromosome 5q deletion is extremely rare in patients with myelofibrosis The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.How to manage the transplant question in myelofibrosis.Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.A three-dimensional block structure consisting exclusively of carbon nanotubes serving as bone regeneration scaffold and as bone defect filler.Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis.Pharmacokinetics and tissue disposition of lenalidomide in mice.Update on JAK2 Inhibitors in Myeloproliferative Neoplasm The evolving role of lenalidomide in the treatment of hematologic malignancies.Myelofibrosis: biology and treatment options.

P2860

Q21198872-89D47303-0871-4312-A9DE-E058C2F096AA Q21285161-14C979E4-5035-478E-90E7-5385CE607B40 Q26863610-1C218243-3A64-427E-B837-6647F13D243D Q27008072-C9FECF87-30E9-4223-8A0D-615F8EC62215 Q33385644-FB2F220D-C061-4278-8982-9F068250007D Q33386057-8773757E-FB2E-4895-A6BD-D856371D57F2 Q33392689-7A8B9EB5-2E48-4E97-A882-E307E4E44C78 Q33401615-B079355B-5D51-4BB5-BB51-A26531B6E706 Q33404574-280DA9C5-D9C1-4124-82D7-0919DD204679 Q33406694-7E35DE02-E4D8-4662-8351-8E9A2BD745BA Q33430113-65E405A1-A428-4196-B6C6-EDB131B8B2F1 Q33432285-F04F7606-097B-4EAF-B92A-0DF50B8F7A2B Q33432406-74F42DA6-4128-4AE6-B2C5-5636879FE1A2 Q33517074-DF78F2AD-5628-48CE-AC18-63143606C712 Q33768543-66937AA4-B6C4-4F30-A451-BFA1B795C920 Q33779309-0F80C519-2F69-427E-9744-75BCDE1E8102 Q33874179-282117DB-9D40-469C-9459-482EB3BCA247 Q34146512-3F74A291-48E0-4FDE-AA69-740FC3D8A4A2 Q34150008-0EC3A7D3-66B2-4641-B61C-DD83DB4881D7 Q34165935-DBF3DFA2-9EBF-4826-B39D-14EB58ACBC11 Q34253548-B09EA307-E4D9-4B6E-A265-04A0029A2714 Q34293419-23880818-4176-4418-B397-3965E9FA6CBD Q34451630-53E0EFF0-AFEB-4B33-A2FA-B6D3A78A1F9A Q34512203-45C3AB5A-688A-4F3A-9915-D337A83EDABA Q34521263-0A61F3CA-F47D-4C50-9BF3-881AC03E5325 Q34625390-794C0D10-72A8-49C7-BE9E-50991E149BB4 Q34734491-D7346E32-DB4E-4A5E-8F9D-0E132512E6DF Q35140955-A4D32BB8-2B99-454B-95FF-F31986FBCC76 Q35203067-FED345D6-97A0-4776-8FDD-4024E6923C54 Q35427915-40A04BF3-76E5-450D-B37C-BBE36A597248 Q35535523-7436CB4D-DB03-4DA0-A2C0-8CA1C5708163 Q35849342-E259684B-A039-4C05-82DC-B47BE384B441 Q35865676-92543CD4-170A-4D39-86B4-0C70E77046E0 Q35988523-1D056E28-3D33-49D0-8D20-91FBF5B94684 Q36290031-275C6AD6-F7BE-4D33-A8C5-55D3090DA328 Q36308248-DB129942-242E-471D-A6D2-4E77A5569C6B Q36331493-7A16EBE1-645C-4A03-A4D1-B4E794B53D6B Q36612569-52927289-E3EA-4E7C-A6B1-B35999877A4F Q36739807-34617BDA-9CE1-40F4-89A0-966648B96217 Q36922494-DC462B3C-6967-493E-9499-E2D8C08D3C5E

P2860

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

http://www.wikidata.org/entity/Q33370821

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

@ast

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

@en

type

label

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

@ast

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

@en

prefLabel

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

@ast

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

@en

P1433

Q33370821-56FC95C8-4BBE-493A-AF5B-C577D6A107E7

P1476

Q33370821-61447FD2-F20B-4D95-A446-A0B90F3744C5

P2093

Q33370821-047C9307-363D-4A8C-B8DC-CF23B174359C

Q33370821-0F85C6E2-0E67-44D5-9136-818D42D985F4

Q33370821-33647476-FDB3-4DEB-9F25-21E8DE5F01DB

Q33370821-65156791-92B3-4DA1-ACCD-C182792EA3B4

Q33370821-65194329-405F-45BD-BDAB-C0D57D05CA40

Q33370821-865338B0-82AE-49BE-A2BE-2DBBC55C4A36

Q33370821-BC4DF1D5-7068-4A4F-8D3F-E4616C2820C9

Q33370821-BCE4D74E-55B5-4BD1-AB5E-2CE412689844

Q33370821-CF7E1347-56AC-4333-A6A9-E04FF9FFBFE8

Q33370821-FC5C054C-836A-4834-B11E-A5952E0DD598

P304

Q33370821-F739D975-A495-4DFF-B3DB-86764D8295DC

P31

Q33370821-53DD4CE6-A48F-4B84-879D-E061DF77603A

P356

Q33370821-483EA6DA-FD62-4228-9DEC-835FECBF5E83

P407

Q33370821-869A8BD6-AB53-47C0-BE1B-87931D130046

P433

Q33370821-B056D052-D525-4A21-AC55-0D2C52A149DD

P478

Q33370821-75EB0FD8-AE22-4FD6-BF8F-0648475DF60B

P50

Q33370821-25B97C17-8005-47AA-A0A3-BA12798DD9CB

Q33370821-519280FA-478A-40FE-89AD-8E38D8170BAB

Q33370821-68E7419C-299E-47AE-A3CA-170B5791BE70

Q33370821-72097CA9-A3BA-45AC-97BA-0689DC7D9A66

Q33370821-BBD90AD5-39E5-4651-A4DF-A53979A8C0B5

Q33370821-F67783EC-968D-41CE-86C0-442DE1F603FE

P577

Q33370821-80AE096F-100A-42CB-AC7C-D2D19DC8F43A

P5875

Q33370821-620C0D94-4413-4514-8F6F-4280E03775D5

P698

Q33370821-EFF37258-BF78-4A2D-B485-E7FED9E1BAA2

P356

BLOOD-2006-02-004572

P1433

P1476

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

@en

P2093

Catriona Byrne

http://www.w3.org/2001/XMLSchema#string

Dan Jones

http://www.w3.org/2001/XMLSchema#string

Deborah Thomas

http://www.w3.org/2001/XMLSchema#string

Jacob B Allred

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Mark R Litzow

http://www.w3.org/2001/XMLSchema#string

Rebecca F McClure

http://www.w3.org/2001/XMLSchema#string

Ruben A Mesa

http://www.w3.org/2001/XMLSchema#string

Terra L Lasho

http://www.w3.org/2001/XMLSchema#string

William J Hogan

http://www.w3.org/2001/XMLSchema#string

P304

1158-1164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-02-004572

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Rhett P. Ketterling

Jorge Eduardo Cortes

Hagop Kantarjian

Srdan Verstovsek

P577

2006-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7171228

http://www.w3.org/2001/XMLSchema#string

P698

16609064

http://www.w3.org/2001/XMLSchema#string